Unicycive Therapeutics stock trades near USD 5.26
Published on 09/02/2026 at 18:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Unicycive Therapeutics stock (US90467V1098) traded at USD 5.26 with a market capitalization of USD 146.52 million on September 1, 2026. MarketBeat also showed a 52-week range of USD 3.71 to USD 8.74 and volume of 608,830 shares.
Analysts still see upside
According to MarketBeat, the consensus rating is Moderate Buy and the average price target is USD 18.75, which implies about 256.5 percent upside from USD 5.26. The same page lists 5 buy ratings, 1 hold rating and 1 sell rating.
Q2 2026 stays small
Yahoo Finance's analyst snapshot for Unicycive Therapeutics shows average revenue estimates of USD 275.38k for the current quarter ending September 2026 and USD 145.41 million for 2027. The same table shows year-ago sales of USD 275.38k and a current-quarter EPS estimate of minus USD 0.31.
Conference date in September
Unicycive Therapeutics said on September 1, 2026 that it will present at the H.C. Wainwright 28th Annual Global Investment Conference. That date gives the stock a visible near-term event anchor even as the trading data stay the main frame for investors.
UNICYCIVE THERAPEUTICS
Unicycive Therapeutics focuses on kidney-disease therapies, and MarketBeat describes the company as a biotechnology group developing novel treatments for kidney diseases in the United States. For investors, the key contrast is still the gap between the USD 5.26 share price and the USD 18.75 consensus target.
Stock level on September 1, 2026
Unicycive Therapeutics stock closed or last traded at USD 5.26 on September 1, 2026, with a market capitalization of USD 146.52 million. The 52-week range of USD 3.71 to USD 8.74 keeps the chart in a wide band.
Unicycive Therapeutics at a glance
- Company: Unicycive Therapeutics, Inc.
- ISIN: US90467V1098
- Ticker: UNCY
- Trading venue: NASDAQ
- Price (as of September 1, 2026): USD 5.26
- Market capitalization: USD 146.52 million (as of September 1, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Not in a major U.S. benchmark index
